Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Dow
US Department of Justice
Cipla
Teva
Federal Trade Commission
Johnson and Johnson
Baxter
Cerilliant

Generated: May 23, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,545,628

« Back to Dashboard

Summary for Patent: 5,545,628
Title: Pharmaceutical composition containing fenofibrate
Abstract:A pharmaceutical composition is provided for treating hyperlipidemia or hypercholesterolemia or both in a mammal, which contains an effective amount of each of fenofibrate and an excipient containing one or more polyglycolyzed glycerides.
Inventor(s): Deboeck; Arthur (Carolina, PR), Maes; Paul (Carolina, PR), Baudier; Phillipe R. (Carolina, PR)
Assignee: Galephar P.R. Inc. (Carolina, PR)
Application Number:08/370,883
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,545,628
Patent Claims: 1. A pharmaceutical composition for treating hyperlipidemia or hypercholesterolemia or both in a mammal, which comprises an effective amount of each of fenofibrate and an excipient comprising one or more polyglycolyzed glycerides.

2. The composition of claim 1, wherein said fenofibrate is present in an amount of 5% to 95% by weight based on the total weight of the composition.

3. The composition of claim 1, wherein the polyglycolyzed glycerides have a HLB value of at least 10.

4. The composition of claim 3, wherein the polylglycolyzed glycerides have a HLB value of from 12 to 15.

5. The composition of claim 1, which further comprises polyalkylene glycols to adjust the HLB value or melting point or both to the desired value.

6. The composition of claim 1, wherein a suspension stabilizer is added.

7. The composition of claim 6, wherein said suspension stabilizer is selected from the group and consisting of cellulose, povidone, poloxamers, .alpha., .OMEGA.-hydroxy-poly(oxyethylene) poly(oxypropylene)-poly(oxyethylene)bloc polymers.

8. The composition of claim 1, in which said fenofibrate and said excipient are in unit dosage form and are contained in a hard gelatin capsule.

9. The composition of claim 8, wherein said hard gelatin capsule contains from about 67 mg to about 200 mg of fenofibrate.

10. A method of making a solid oral dosage form of a pharmaceutical composition, comprising an effective amount of each of fenofibrate and an excipient comprising one or more polyglycolyzed glycerides, which method comprises adding said molten fenofibrate and said excipient to hard gelatin capsules, and allowing said said molten fenofibrate and said excipient to cool therein.

11. A method of treating hyperlipidemia or hypercholesterolemia or both in a mammal in need threof, which comprises administering to said mammal an effective amount of a pharmaceutical composition, comprising fenofibrate and an excipient containing one or more polyglycolyzed glycerides.

12. The method of claim 11, wherein said mammal is human, and said effective amount of fenofibrate in said composition is from about 100 mg to 600 mg per day.

13. The method of claim 12, wherein said effective amount of fenofibrate in said composition is from about 100 mg to 300 mg per day.

14. The method of claim 11, wherein said composition is administered orally.

15. The method of claim 10, which is with the proviso that the fenofibrate used is not co-micronized.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Cipla
Deloitte
Daiichi Sankyo
Merck
Argus Health
Moodys
Express Scripts
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.